Christopher A. Kuebler, Director at NEKTAR THERAPEUTICS (NKTR), sold 12,500 shares at $10.66 ($133K) on 2012-09-27, disclosed to the SEC on 2012-10-01.
Scheduled sale ($133k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| WAT | SELL | 2023-08-07 | $1.2M | — | Filing → |
| WAT | SELL | 2022-05-23 | $1.3M | — | Filing → |
| WAT | SELL | 2021-08-19 | $1.2M | — | Filing → |